Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli that produce single-domain antibodies

Infection and Immunity

Volumn 84, Issue 2, 2016, Pages 395-406

  Andersen, Kasper Krogh ^a   Strokappe, Nika M ^b   Hultberg, Anna ^b   Truusalu, Kai ^c   Smidt, Imbi ^c   Mikelsaar, Raik Hiio ^c   Mikelsaar, Marika ^c   Verrips, Theo ^b   Hammarström, Lennart ^a   Marcotte, Harold ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; NANOBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VARIABLE DOMAIN OF HEAVY CHAIN ANTIBODY; ANTITOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT PROTEIN; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL SPORE; BACTERIAL STRAIN; BIOENGINEERING; CLOSTRIDIUM DIFFICILE INFECTION; COLON MUCOSA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DRUG BINDING; DRUG EFFECT; GASTROINTESTINAL TRACT; HAMSTER MODEL; IN VITRO STUDY; INFECTION; INFLAMMATION; LACTOBACILLUS; LACTOBACILLUS PARACASEI; LLAMA; MALE; NONHUMAN; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROPHYLAXIS; ANIMAL; DISEASE MODEL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ESCHERICHIA COLI; GENETICS; HAMSTER; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEW WORLD CAMELID; ORAL DRUG ADMINISTRATION; PATHOGENICITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CAMELIDS, NEW WORLD; CLOSTRIDIUM DIFFICILE; CRICETINAE; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; IMMUNIZATION; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN HEAVY CHAINS; LACTOBACILLUS; RECOMBINANT PROTEINS; SINGLE-DOMAIN ANTIBODIES;

EID: 84957657351     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00870-15     Document Type: Article

References (51)

1. Ozaki E, Kato H, Kita H, Karasawa T, Maegawa T, Koino Y, Matsumoto K, Takada T, Nomoto K, Tanaka R, Nakamura S. 2004. Clostrid-ium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol 53:167-172. http://dx.doi.org/10.1099/jmm.0.05376-0.
2. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Beliveau C, Oughton M, Brukner I, Dascal A. 2011. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693-1703. http://dx.doi.org/10.1056/NEJMoa1012413.
3. Lucado J, Gould C, Elixhauser A. 2006. Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare Cost and Utilization Project (HCUP) statistical briefs, statistical brief #124. Agency for Healthcare Research and Quality, Rockville, MD.
4. Hickson M. 2011. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Ther Adv Gastroenterol 4:185-197. http://dx.doi.org/10.1177/1756283X11399115.
5. Kyne L. 2010. Clostridium difficile-beyond antibiotics. N Engl J Med 362:264-265. http://dx.doi.org/10.1056/NEJMe0910055.
6. Carter GP, Rood JI, Lyras D. 2012. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 20:21-29. http://dx.doi.org/10.1016/j.tim.2011.11.003.
7. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. http://dx.doi.org/10.1038/nature07822.
8. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010 The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
9. O'Connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136:1913-1924. http://dx.doi.org/10.1053/j.gastro.2009.02.073.
10. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09.
11. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. http://dx.doi.org/10.1016/S0140-6736(05)67420-X.
12. Gerding DN. 2004. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 38:646-648. http://dx.doi.org/10.1086/382084.
13. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
14. Gough E, Shaikh H, Manges AR. 2011. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994-1002. http://dx.doi.org/10.1093/cid/cir632.
15. Kassam Z, Lee CH, Yuan Y, Hunt RH. 2013. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and metaanalysis. Am J Gastroenterol 108:500-508. http://dx.doi.org/10.1038/ajg.2013.59.
16. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635.
17. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. http://dx.doi.org/10.1016/S0140-6736(00)03592-3.
18. Kelly CP, Kyne L. 2011. The host immune response to Clostridium difficile. J Med Microbiol 60:1070-1079. http://dx.doi.org/10.1099/jmm.0.030015-0.
19. van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P, van't Wout J. 2005. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54:197-205. http://dx.doi.org/10.1099/jmm.0.45773-0.
20. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. 2007 Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 56:888-889 http://dx.doi.org/10.1136/gut.2006.119016.
21. Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG. 2006. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol 72:544-551. http://dx.doi.org/10.1007/s00253-005-0300-7.
22. Hussack G, Hirama T, Ding W, Mackenzie R, Tanha J. 2011. Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One 6:e28218. http://dx.doi.org/10.1371/journal.pone.0028218.
23. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarstrom L. 2006. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 194:1580-1588 http://dx.doi.org/10.1086/508747.
24. Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6:349-362 http://dx.doi.org/10.1038/nrmicro1840.
25. Genth H, Selzer J, Busch C, Dumbach J, Hofmann F, Aktories K, Just I. 2000. New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization. Infect Immun 68:1094-1101 http://dx.doi.org/10.1128/IAI.68.3.1094-1101.2000.
26. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T. 2012. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One 7:e33298. http://dx.doi.org/10.1371/journal.pone.0033298.
27. Chomczynski P, Sacchi N. 2006. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1:581-585. http://dx.doi.org/10.1038/nprot.2006.83.
28. Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, den Dunnen JT, Frants RR, Verkleij AJ, Theo Verrips C, van der Maarel SM. 2006. Reliable and controllable antibody fragment selections from camelid nonimmune libraries for target validation. Biochim Biophys Acta 1764:1307-1319 http://dx.doi.org/10.1016/j.bbapap.2006.05.011.
29. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. 1991. By-passing immunization. Human antibodies from Vgene libraries displayed on phage. J Mol Biol 222:581-597.
30. Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibanez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ. 2011. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 6:e17665. http://dx.doi.org/10.1371/journal.pone.0017665.
31. Martin MC, Pant N, Ladero V, Gunaydin G, Andersen KK, Alvarez B, Martinez N, Alvarez MA, Hammarstrom L, Marcotte H. 2011. Integrative expression system for delivery of antibody fragments by lactobacilli. Appl Environ Microbiol 77:2174-2179. http://dx.doi.org/10.1128/AEM.02690-10.
32. Marcotte H, Koll-Klais P, Hultberg A, Zhao Y, Gmur R, Mandar R, Mikelsaar M, Hammarstrom L. 2006. Expression of single-chain antibody against RgpA protease of Porphyromonas gingivalis in Lactobacillus. J Appl Microbiol 100:256-263. http://dx.doi.org/10.1111/j.1365-2672.2005.02786.x.
33. Andersen KK, Marcotte H, Alvarez B, Boyaka PN, Hammarstrom L. 2011 In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli. BMC Biotechnol 11:126. http://dx.doi.org/10.1186/1472-6750-11-126.
34. Whitaker AM, Hayward CJ. 1985. The characterization of three monkey kidney cell lines. Dev Biol Stand 60:125-131.
35. Torres J, Camorlinga-Ponce M, Munoz O. 1992. Sensitivity in culture of epithelial cells from rhesus monkey kidney and human colon carcinoma to toxins A and B from Clostridium difficile. Toxicon 30:419-426. http://dx.doi.org/10.1016/0041-0101(92)90538-G.
36. Baines SD, Freeman J, Wilcox MH. 2005. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 55:974-982. http://dx.doi.org/10.1093/jac/dki120.
37. Gorlani A, Hulsik DL, Adams H, Vriend G, Hermans P, Verrips T. 2012 Antibody engineering reveals the important role of J segments in the production efficiency of llama single-domain antibodies in Saccharomyces cerevisiae. Protein Eng Des Sel 25:39-46. http://dx.doi.org/10.1093/protein/gzr057.
38. Sambol SP, Tang JK, Merrigan MM, Johnson S, Gerding DN. 2001. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis 183:1760-1766. http://dx.doi.org/10.1086/320736.
39. Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. 1998. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 47:591-598. http://dx.doi.org/10.1099/00222615-47-7-591.
40. Price AB, Larson HE, Crow J. 1979. Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut 20:467-475 http://dx.doi.org/10.1136/gut.20.6.467.
41. Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP. 2008 Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 52: 207-218. http://dx.doi.org/10.1111/j.1574-695X.2007.00363.x.
42. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339-6347. http://dx.doi.org/10.1128/IAI.00982-06.
43. Best EL, Freeman J, Wilcox MH. 2012. Models for the study of Clostridium difficile infection. Gut Microbes 3:145-167. http://dx.doi.org/10.4161/gmic.19526.
44. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018-2025.
45. Li X, Nakano T, Sunwoo HH, Paek BH, Chae HS, Sim JS. 1998. Effects of egg and yolk weights on yolk antibody (IgY) production in laying chickens. Poul Sci 77:266-270. http://dx.doi.org/10.1093/ps/77.2.266.
46. Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I, LaMont JT, Pothoulakis C. 1997. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 41:236-241.
47. Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H. 2014. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 210:964-972. http://dx.doi.org/10.1093/infdis/jiu196.
48. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. 1991. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 59:2215-2218.
49. Mulvey GL, Dingle TC, Fang L, Strecker J, Armstrong GD. 2011. Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection. J Med Microbiol 60:1181-1187. http://dx.doi.org/10.1099/jmm.0.029835-0.
50. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J. 2011. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286:8961-8976. http://dx.doi.org/10.1074/jbc. M110.198754.
51. Douce G, Goulding D. 2010. Refinement of the hamster model of Clostridium difficile disease. Methods Mol Biol 646:215-227. http://dx.doi.org/10.1007/978-1-60327-365-7_14.